Prognostic value and immunomodulatory role of DNAJC5B in esophageal squamous cell carcinoma
- VernacularTitle:DNAJC5B在食管鳞状细胞癌中的预后价值及免疫调节作用
- Author:
Junxi HU
1
;
Qingwen LIU
2
;
Jiaqi HOU
2
;
Jie YOU
2
;
Shuyu TIAN
2
;
Hao KONG
3
;
Xiaolin WANG
1
,
3
;
Yusheng SHU
1
,
3
Author Information
1. Department of Thoracic Surgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221006, Jiangsu, P. R. China
2. Dalian Medical University, Dalian, 116044, Liaoning, P. R. China
3. Department of Thoracic Surgery, Northern Jiangsu People's Hospital, Yangzhou, 225000, Jiangsu, P. R. China
- Publication Type:Journal Article
- Keywords:
DNAJC5B;
esophageal squamous cell carcinoma;
tumor immunity;
prognosis;
immunotherapy
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2026;33(10):1634-1639
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the role of DNAJC5B in immunotherapy for esophageal squamous cell carcinoma (ESCC). Methods Using the ESCC dataset from The Cancer Genome Atlas (TCGA) database, genes correlated with DNAJC5B expression were identified through Pearson correlation analysis. Subsequently, Gene Ontology (GO) functional enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were performed. Additionally, single-cell RNA sequencing (scRNA-seq) data were utilized to analyze the expression of DNAJC5B in different T-cell subsets. The prognostic value of DNAJC5B was evaluated using Kaplan-Meier survival curves, receiver operating characteristic curves, and Cox proportional hazards models. Results DNAJC5B was highly expressed in patients with advanced-stage ESCC, particularly in males. GO and KEGG analyses revealed a significant correlation between DNAJC5B expression and immune-related processes, such as the adaptive immune response and cell surface receptor signaling pathways. Single-cell analysis results indicated that DNAJC5B expression was positively correlated with immune function, with DNAJC5B predominantly accumulating in CD8+ T cells. Kaplan-Meier survival curves showed that the median survival time for patients with high DNAJC5B expression was 681 days, significantly shorter than the 1 361 days for patients with low expression (P<0.05). Furthermore, univariate and multivariate independent prognostic analyses demonstrated that DNAJC5B was an independent risk factor, with hazard ratios (HRs) of 3.577 and 4.114, respectively (both P<0.05). Conclusion DNAJC5B may play a crucial immunomodulatory role in ESCC, particularly in regulating CD8+ T-cell function and tumor immune escape. These findings support the potential of DNAJC5B as a biomarker for the treatment and prognostic assessment of ESCC.
